Phase II clinical research design in cardiology learning the right lessons too well: Observations and recommendations from the cardiovascular cell therapy research network (CCTRN)

Circulation

Volumn 127, Issue 15, 2013, Pages 1630-1635

  Hare, Joshua M ^a   Bolli, Roberto ^b   Cooke, John P ^c   Gordon, David J ^j   Henry, Timothy D ^d,e   Perin, Emerson C ^f   March, Keith L ^g   Murphy, Michael P ^g   Pepine, Carl J ^h   Simari, Robert D ⁱ   Skarlatos, Sonia I ^j   Traverse, Jay H ^d,e   Willerson, James T ^f   Szady, Anita D ^h   Taylor, Doris A ^f   Vojvodic, Rachel W ^k   Yang, Phillip C ^c   Moyé, Lemuel A ^k  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f TEXAS HEART INSTITUTE   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁱ MAYO CLINIC   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^k UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Clinical trials, phase II; Research design; Stem cell; Therapy

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CARDIOLOGY; CARDIOVASCULAR DISEASE; CELL THERAPY; DECISION MAKING; DISEASE MARKER; DRUG INDUSTRY; FUNDING; HEART FAILURE; HEART INFARCTION; HUMAN; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; ENDPOINT DETERMINATION; HEART FUNCTION TESTS; HUMANS; MULTICENTER STUDIES AS TOPIC; QUALITY OF LIFE; RESEARCH DESIGN; SAMPLE SIZE; STEM CELL TRANSPLANTATION;

EID: 84876268473     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.000779     Document Type: Article

References (31)

1. Five-year fndings of the hypertension detection and follow-up program, I: reduction in mortality of persons with high blood pressure, including mild hypertension: Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242:2562-2571.
2. Davis B, Cutler JA, Gordon D. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravas-tatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1308.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
5. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial: the SAVE Investigators. N Engl J Med. 1992;327:669-677.
6. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure: SOLVD Investigators. Circulation. 1992;86:431-438.
7. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results: Multiple Risk Factor Intervention Trial Research Group. JAMA. 1982;248:1465-1477.
8. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP. Effects of vesnarinone on morbidity and mortality in patients with heart failure: Vesnarinone Study Group. N Engl J Med. 1993;329:149-155.
9. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F 3rd, DeMets DL, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators. N Engl J Med. 1998;339:1810-1816.
10. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
11. Preliminary report: effect of encainide and fecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction: the Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989;321:406-412.
12. Moore TJ. Deadly Medicine: Why Tens of Thousands of Heart Patients Died in America's Worst Drug Disaster. New York, New York: Simon & Schuster; 1995.
13. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
14. Cardiovascular and Renal Drugs Advisory Committee [transcript]. May2, 1996.
15. Moyé LA, Abernethy D. Carvedilol in patients with chronic heart failure. N Engl J Med. 1996;335:1318.
16. Packer M, Cohn JN, Colucci WS. Response to Moyé and Abernethy. N Engl J Med. 1996; 335: 1318-1319.
17. Fisher LD, Moyé LA. Carvedilol and the Food and Drug Administration approval process: an introduction. Control Clin Trials. 1999;20:1-15.
18. Fisher LD. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and refections on hypothesis testing. Control Clin Trials. 1999;20:16-39.
19. Moyé LA. End-point interpretation in clinical trials: the case for discipline. Control Clin Trials. 1999;20:40-49.
20. Mills JL. Data torturing. N Engl J Med. 1993;329:1196-1199.
21. Yusuf S, Wittes J, Probstfeld J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93-98.
22. Moyé LA, Deswal A. Trials within trials: confrmatory subgroup analyses in controlled clinical experiments. Control Clin Trials. 2001;22:605-619.
23. Packer M. Proposal for a new clinical end point to evaluate the effcacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7:176-182.
24. Lauer MS. From hot hands to declining effects: the risks of small numbers. J Am Coll Cardiol. 2012;60:72-74.
25. 2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313.
26. Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of tran-sendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307:1717-1726.
27. Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Ba-raniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD; Cardiovascular Cell Therapy Research Network. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myo-cardial infarction. Tex Heart Inst J. 2010;37:412-420.
28. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308:2380-2389.
29. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-2379.
30. Cutler DM. The demise of the blockbuster? N Engl J Med. 2007;356:1292-1293.
31. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.